(616 Kb) -

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). : A major finding was that 41% of

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. (616 KB)

The search for a "616 KB" article points directly to a significant medical study titled

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials